Compare First Citizens BancShares Inc (FCNCA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Novo Nordisk A/S — how do they compare? First Citizens BancShares Inc trades at $2,252.45 (market cap $25.04B), while Novo Nordisk A/S trades at $45.97 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.3× First Citizens BancShares Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| FCNCA | NVO | |
|---|---|---|
Market Cap | $25.04B | $207.85B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $63.98 |
52-Week Low | $1.64K | $35.29 |
Dividend Yield | 0.37% | 3.81% |
Enterprise Value | — | $222.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,258.55, up 1.13% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by positive cash flow trends and strategic expansions in commercial banking services. Recent news highlights institutional investments and new leadership appointments, reinforcing growth initiatives.
Outlook remains favorable due to consistent earnings outperformance and expanding business segments, though risks include elevated uninsured deposits and net interest margin pressure. Analyst consensus is mixed with a hold-heavy rating, but the stock offers value with upside to the $2,310 price target. Investors should weigh solid profitability against sector-specific headwinds.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
